Special PET scan for tumor-induced osteomalacia
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests a new PET/CT scan (using a tracer called Al18F-NOTA-LM3) to better find tumors causing TIO, a condition that leads to bone softening and weakness. It may help doctors diagnose and treat TIO more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a suspected or confirmed diagnosis of tumor-induced osteomalacia (TIO).
- You do not have any other type of tumor.
- You do not have severe liver or kidney problems.
- You are not pregnant or breastfeeding.
- You are able to lie still for a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This study tests a new type of PET scan using a special tracer called Al18F-NOTA-FAPI-04 to see if it can better detect cancer, heart disease, or immune system conditions. The goal is to find out how well this imaging method works for diagnosis or monitoring of these diseases.
This trial uses a special PET scan to see if a new imaging agent can find hard-to-treat pituitary tumors that have come back after surgery. It may help doctors decide the best way to manage these tumors.
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
This trial uses a special PET/CT scan called Al18F-NOTA-LM3 to help doctors see pheochromocytoma and paraganglioma tumors more clearly. It may help find out if you have these tumors and guide your treatment.
This trial tests a new imaging tracer called TATE-RGD to see if it can better spot certain tumors when used with a standard PET/CT scan. If you have cancer, you may be able to help by getting two scans a week apart.
Hear when a new Tumor-Induced Osteomalacia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.